Key result
Non-alcoholic fatty liver disease is strongly associated with an increased risk of extra-hepatic diseases including type 2 diabetes, cardiovascular disease, and chronic kidney disease.
Answers are grounded in this paper and cite their sources.
NAFLD is an emerging risk factor for cardiometabolic and renal diseases, emphasizing the need for multidisciplinary screening and management in affected patients.
As the number of individuals with non-alcoholic fatty liver disease (NAFLD) has increased, the influence of NAFLD on other metabolic diseases has been highlighted. Accumulating epidemiologic evidence indicates that NAFLD not only affects the liver but also increases the risk of extra-hepatic diseases such as type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, hypertension, cardiovascular or cerebrovascular diseases, and chronic kidney disease. Non-alcoholic steatohepatitis, an advanced type of NAFLD, can aggravate these inter-organ relationships and lead to poorer outcomes. NAFLD induces insulin resistance and exacerbates systemic chronic inflammation and oxidative stress, which leads to organ dysfunction in extra-hepatic tissues. Although more research is needed to identify the pathophysiological mechanisms and causal relationship between NAFLD and cardiometabolic and renal diseases, screening for heart, brain, and kidney diseases, risk assessment for diabetes, and a multidisciplinary approach for managing these patients should be highly encouraged.
No takes yet. Share an insight, caveat, or question.
Han et al. (2017) conducted a review in Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic fatty liver disease (NAFLD) vs. Absence of NAFLD was evaluated. Non-alcoholic fatty liver disease is strongly associated with an increased risk of extra-hepatic diseases including type 2 diabetes, cardiovascular disease, and chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: